Aseptic meningitis as a complication of daratumumab therapy

The treatment of relapsed multiple myeloma has been greatly improved by the use of targeted antibody therapy. Daratumumab is a humanized IgG monoclonal antibody that targets CD38, a transmembrane protein expressed on many cell types including myeloma cells, hematopoietic progenitor cells, and endothelial cells.1 It shows single-agent activity in highly advanced myeloma, leading to FDA approval.2 It was also approved in combination with standard myeloma drugs such as lenalidomide, pomalidomide, and bortezomib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research